| Dr Leonardo Garcia-mendez, MD | |
|
2010 S Cynthia St Ste 106, Mcallen, TX 78503-1387 | |
| (956) 687-3318 | |
| (956) 687-4878 |
| Full Name | Dr Leonardo Garcia-mendez |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 56 Years |
| Location | 2010 S Cynthia St Ste 106, Mcallen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083799001 | NPI | - | NPPES |
| 089894202 | Medicaid | TX | |
| OOU84G | Other | TX | BLUE CROSS PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0402X | Psychiatry & Neurology - Neurology With Special Qualifications In Child Neurology | 2084N0402X (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital At Renaissance | Edinburg, TX | Hospital |
| Entity Name | Lemar Management L.l.c |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922207414 PECOS PAC ID: 0244331478 Enrollment ID: O20070718000492 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
Words+, Inc., a leading provider of augmentative communication and assistive technology hardware and software for people with disabilities, announced today that it has launched EyePro GS™, a new product designed and manufactured in-house that allows a person to operate an augmentative communication system or computer by simply looking at the screen. Words+ is a wholly owned subsidiary of Simulations Plus, Inc..
Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.
A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences today (Monday).
› Verified 9 days ago
| Entity Name | Lg Neuromet Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700336997 PECOS PAC ID: 2769760263 Enrollment ID: O20161104000380 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
Words+, Inc., a leading provider of augmentative communication and assistive technology hardware and software for people with disabilities, announced today that it has launched EyePro GS™, a new product designed and manufactured in-house that allows a person to operate an augmentative communication system or computer by simply looking at the screen. Words+ is a wholly owned subsidiary of Simulations Plus, Inc..
Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.
A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences today (Monday).
› Verified 9 days ago
| Entity Name | Leonardo Garcia Md., Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063909208 PECOS PAC ID: 2062769680 Enrollment ID: O20180727000037 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
Words+, Inc., a leading provider of augmentative communication and assistive technology hardware and software for people with disabilities, announced today that it has launched EyePro GS™, a new product designed and manufactured in-house that allows a person to operate an augmentative communication system or computer by simply looking at the screen. Words+ is a wholly owned subsidiary of Simulations Plus, Inc..
Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.
A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences today (Monday).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leonardo Garcia-mendez, MD 2010 S Cynthia St Ste 106, Mcallen, TX 78503-1387 Ph: (956) 687-3318 | Dr Leonardo Garcia-mendez, MD 2010 S Cynthia St Ste 106, Mcallen, TX 78503-1387 Ph: (956) 687-3318 |
News Archive
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
Words+, Inc., a leading provider of augmentative communication and assistive technology hardware and software for people with disabilities, announced today that it has launched EyePro GS™, a new product designed and manufactured in-house that allows a person to operate an augmentative communication system or computer by simply looking at the screen. Words+ is a wholly owned subsidiary of Simulations Plus, Inc..
Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.
A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences today (Monday).
› Verified 9 days ago
Hildebrando Salinas, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2010 S Cynthia St, Ste #104, Mcallen, TX 78503 Phone: 956-972-0061 Fax: 956-972-0069 | |
Gloria Patricia Simms, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5405 N Mccoll Rd, Mcallen, TX 78504 Phone: 956-362-8500 Fax: 956-362-8735 | |
Dr. Hamzah Muhammad Saei, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 101 E Ridge Rd Ste B, Mcallen, TX 78503 Phone: 956-682-5665 | |
Rosalinda Flores, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 W Expressway 83, Mcallen, TX 78503 Phone: 956-632-4000 Fax: 956-961-4286 | |
Christie Ann Ybarra, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 901 E. Hackberry, Bhip Clinic, Mcallen, TX 78501 Phone: 956-618-7100 | |
Dr. Tommy Yee, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1913 S 1st St, Suite 200, Mcallen, TX 78503 Phone: 956-686-2393 |